Can venous ProBNP levels predict placenta accreta?

Ersoy, Ali Özgür; Öztaş, Efser; Özler, Sibel; Ersoy, Ebru; Erkenekli, Kudret; Uygur, Dilek; Çağlar, Ali Turhan; Danışman, Nuri

doi:10.3109/14767058.2016.1152576

Cited by 23 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have shown variable reliability and variability of measurement depending on gestational age at sampling. At present, a sensitive serum biomarker for invasive placentation remains elusive [ 58 , 70 , 94 ]. With further supporting data from larger study populations, it may be possible for biomarkers to be combined with sonographic and MRI imaging to screen for PAS antenatally in a model similar to that used for aneuploidy screening.…”

Section: Discussionmentioning

confidence: 99%

“…Circulating cell-free placental mRNA has emerged as a potential marker because it can be stably isolated and quantified from maternal plasma [ 90 – 94 ]. El Behery et al investigated whether measuring cell-free placental mRNA in maternal plasma improved the diagnostic accuracy of ultrasound and colour Doppler in detecting placental invasion in patients at risk for PAS [ 94 ]. Thirty-five singleton pregnant women (7 with confirmed PAS) of more than 28 weeks of gestation and at risk of PAS underwent ultrasound and colour Doppler assessment.…”

Section: Biomarkersmentioning

confidence: 99%

“…In 2012, Zhou et al measured cell-free β -HCG mRNA concentrations from maternal plasma samples at 28–30 weeks gestational age to determine their applicability for antenatal diagnosis of PAS ( n = 12) when compared with patients with placenta previa alone ( n = 21) and with women with prior CD and normal placentation ( n = 35) [ 94 ]. The plasma mRNA levels of β -HCG were found to be higher in the PAS group, whereas no significant difference was detected in the plasma β -HCG protein levels.…”

Section: Biomarkersmentioning

confidence: 99%

See 2 more Smart Citations

Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers

et al. 2018

View full text Add to dashboard Cite

Background. Placenta accreta spectrum (PAS) is a condition of abnormal placental invasion encompassing placenta accreta, increta, and percreta and is a major cause of severe maternal morbidity and mortality. The diagnosis of a PAS is made on the basis of histopathologic examination and characterised by an absence of decidua and chorionic villi are seen to directly adjacent to myometrial fibres. The underlying molecular biology of PAS is a complex process that requires further research; for ease, we have divided these processes into angiogenesis, proliferation, and inflammation/invasion. A number of diagnostic serum biomarkers have been investigated in PAS, including human chorionic gonadotropin (HCG), pregnancy-associated plasma protein-A (PAPP-A), and alpha-fetoprotein (AFP). They have shown variable reliability and variability of measurement depending on gestational age at sampling. At present, a sensitive serum biomarker for invasive placentation remains elusive. In summary, there are a limited number of studies that have contributed to our understanding of the molecular biology of PAS, and additional biomarkers are needed to aid diagnosis and disease stratification.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Biomarkersmentioning

confidence: 99%

Section: Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Vascular endothelial growth factor (VEGF) and N-terminal pro B-type natriuretic peptide (NT-proBNP) are known to play a role in the process of placentation [17][18][19][20]. Both show altered serum levels in AIP cases, having potential as promising biomarker candidates [21,22]. However, there has been no evaluation of these candidates against the background of different degrees of invasion of AIP, and their ability to predict AIP has yet to be comprehensively compared.…”

Section: Introductionmentioning

confidence: 99%

Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study

et al. 2020

View full text Add to dashboard Cite

The aim of this study was to test if maternal serum vascular endothelial growth factor (VEGF) or N-terminal pro B-type natriuretic peptide (NT-proBNP) predicts abnormally invasive placenta (AIP) better. Secondary objective was to test whether the serum levels of VEGF and NT-proBNP can predict the degree of invasion. In a multicenter case–control study design, gestational age-matched serum samples from pregnant women with AIP (n = 44) and uncomplicated pregnancies (n = 55) who had been enrolled at Charité – Universitätsmedizin Berlin, Germany and Centre Hospitalier Régional de la Citadelle in Liège, Belgium were analyzed. Maternal blood serum VEGF and NT-proBNP levels were immunoassayed from samples taken immediately before delivery (GA median: 35 weeks). Biomarker levels were compared between AIP and control group. The correlation of biomarker levels with the clinical AIP degree was assessed. The predictive biomarker ability was characterized through a multivariate regression model and receiver operating characteristic curves. Women with AIP had significantly lower maternal serum VEGF levels (AIP mean 285 pg/ml, 95% CI 248–322, vs. control: 391 pg/ml, 95% CI 356–426, p < 0.01) and higher NT-proBNP levels (AIP median 329 pg/ml, IQR 287–385, vs. control 295 pg/ml, IQR 273–356, p = 0.03). Maternal serum VEGF levels were able to predict AIP better (AUC = 0.729, 0.622–0.836, p < 0.001; VEGF + number of previous cesarean deliveries: AUC = 0.915, 0.853–0.977, p < 0.001). Maternal serum VEGF levels correlated inversely with the clinical AIP degree (r = − 0.32, p < 0.01). In short, maternal serum VEGF, more than NT-proBNP, can help in predicting AIP and hints at the degree of invasion.

show abstract

“…At present, a sensitive serum biomarker for invasive placentation remains elusive. (13,14) The objective of this study was to identify a risk group of women with a previous cesarean delivery for PAS and find the optimum surgical way to preserve a reproductive function.…”

Section: Introductionmentioning

confidence: 99%

The Results of Surgical Treatment of Placenta Accreta in Women with a Previous Cesarean Delivery

Ignatieva¹,

Douglas²,

Neustroeva³

et al. 2019

IJBM

View full text Add to dashboard Cite

This article presents the results of surgical treatment of placenta accreta in 18 women with a previous cesarean delivery according to the data of the Departments of gynecology at the Yakutsk Republican Clinical Hospital and Republican Hospital #1 (National health center) of the Republic of Sakha (Yakutia) for the period of 2018-2019. The diagnosis of placenta accreta spectrum (PAS) was based on ultrasound findings and MRI data. Seventeen patients underwent metroplasty. In PAS disorders, metroplasty is fertility-preserving surgery with minimal blood loss both by the laparotomic and laparoscopic approaches.

show abstract

Can venous ProBNP levels predict placenta accreta?

Abstract: Troponin I and ProBNP levels in PP cases were higher than controls and ProBNP could predict placenta accreta.

Cited by 23 publications

References 22 publications

Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers

Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers

Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study

The Results of Surgical Treatment of Placenta Accreta in Women with a Previous Cesarean Delivery

Contact Info

Product

Resources

About